Table 1.
Demographic and clinical characteristics of the included patients
| Whole sample (n = 143) | Included in Ab titer analysis (n = 97) | Excluded from Ab titer analysis (n = 45) | p | |
|---|---|---|---|---|
| F, n (%) | 108 (75.5) | 74 (76.3) | 34 (73.9) | 0.836 |
| Age, mean ± SD | 45 ± 12.1 | 44.4 ± 12.1 | 46.3 ± 12.1 | 0.388 |
| Weight, kg ± SD | 68.1 ± 15.3 | 66.7 ± 13.8 | 71.1 ± 17.9 | 0.127 |
| Any allergy | 28 (20) | 20 (21.3) | 8 (18.2) | 0.821 |
| Any comorbidity | 40 (29) | 24 (25.5) | 16 (36.4) | 0.228 |
| Disease duration, mean ± SD | 12.8 ± 9.8 | 12.4 ± 9.3 | 13.8 ± 10.8 | 0.398 |
|
Disease course RR, n (%) |
131 (91.6) | 92 (94.8) | 39 (86.7) | 0.111 |
| Relapses in the past year, mean ± SD | 0.3 ± 0.6 | 0.3 ± 0.6 | 0.3 ± 0.5 | 0.636 |
| EDSS, median (IQR) | 2.0 (1.5–2.0) | 1.5 (1.5–2.5) | 2.0 (1.5–3.0) | 0.390 |
| Treated with DMTs, n (%) | 125 (88.8) | 90 (93.8) | 35 (76.1) | 0.002 |
| High-efficacy DMTs, n (%) | 67 (54.9) | 55 (61.1) | 12 (37.5) | 0.021 |
| AntiCD20, n (%) | 26 (18.2) | 21 (21.6) | 5 (15.6) | 0.346 |
| Duration of treatment with antiCD20, years, mean ± SD | 2.3 ± 1.6 | 2.3 ± 1.7 | 2.2 ± 1.4 | 0.865 |
| Responders, n (%) | 81 (83.5)* | 81 (83.5)* | n/a | n/a |
| Follow-up (months), mean ± SD | 5.9 ± 1 | 6.1 ± 0.9 | 5.5 ± 1.2 | 0.001 |
*Calculated on 97 patients
Legend: F, females; SD, standard deviation; BMI, body mass index; RR, relapsing-remitting; EDSS, Expanded Disability Status Scale; DMTs, disease-modifying therapies